THERAPY DOSSIER · th-02a418dfd579

Human serum albumin-thioredoxin fusion protein (HSA-Trx)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24361613 ↗2013Reported benefit

Albumin fusion renders thioredoxin an effective anti-oxidative and anti-inflammatory agent for preventing cisplatin-induced nephrotoxicity.

MouseChemical/toxinICRMaleIntravenous

Model: Cisplatin nephropathy induced by a single administration of cisplatin

HSA-Trx attenuated the cisplatin-induced rise in serum creatinine, blood urea nitrogen and urinary N-acetyl-beta-D-glucosaminidase and the fall in creatinine clearance, substantially reduced tubular injury and apoptosis, suppressed renal oxidative stress markers and lowered TNF-alpha, IL-1 beta and…

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…